✦ LIBER ✦

Treatment of Acute Myeloid Leukaemia with Cytosine Arabinoside and Daunomycin in Combination

✍ Scribed by BRINCKER, HANS

Book ID: 114788428
Publisher: Wiley (Blackwell Publishing)
Year: 2009
Weight: 391 KB
Volume: 9
Category: Article
ISSN: 0036-553X
DOI: 10.1111/j.1600-0609.1972.tb00998.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of acute leukaemia withm-AMSA

Treatment of acute leukaemia withm-AMSA in combination with cytosine arabinoside

✍ H. S. Dhaliwal; M. S. Shannon; M. J. Barnett; H. G. Prentice; K. Bragman; J. S. 📂 Article 📅 1986 🏛 Springer 🌐 English ⚖ 442 KB

Treatment of acute myeloid leukemia of a

Treatment of acute myeloid leukemia of adults with cytosine arabinoside in combination with 6-mercaptopurine

✍ John G. Buchanan; John R. D. Matthews; J. Graham Davison; Robert R. Grigor; Thom 📂 Article 📅 1973 🏛 John Wiley and Sons 🌐 English ⚖ 576 KB

Treatment of refractory acute myeloid le

Treatment of refractory acute myeloid leukemia with high-dose cytosine arabinoside and mitoxantrone in combination

✍ W. Hiddemann; H. Kreutzmann; W.D. Ludwig; H.C. Aul; R. Donhuijsen-Ant; E. Lengfe 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 92 KB

TREATMENT OF REFRACTORY ACUTE LEUKAEMIA

TREATMENT OF REFRACTORY ACUTE LEUKAEMIA WITH HIGH DOSE CYTOSINE ARABINOSIDE

✍ R. Willemze; F. E. Zwaan; J. J. Keuning; G. Colpin 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB

CYTOSINE ARABINOSIDE IN THE TREATMENT OF

CYTOSINE ARABINOSIDE IN THE TREATMENT OF ACUTE MYELOBLASTIC LEUKÆMIA

✍ Bailey, C.C.; Israëls, M.C.G.; Brown, M.T.; Geary, C.G.; Whittaker, J.A.; Weathe 📂 Article 📅 1971 🏛 The Lancet 🌐 English ⚖ 598 KB

Clofarabine and high-dose cytosine arabi

Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia

✍ Eric Tse; Anskar Y. H. Leung; Joycelyn Sim; Harold K. K. Lee; Herman S. Y. Liu; 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 98 KB

Clofarabine (40 mg/m^2^/day × 5) and high-dose cytosine arabinoside (Ara-C, 1–2 g/m^2^/day × 5) were used in 10 men and 11 women, at a median age of 45 (22–62) years, with refractory (__N__ = 4) and relapsed (__N__ = 17) acute myeloid leukaemia, after a median of 3 (2–5) prior regimens. Grade 4 myel